Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 80

1.

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.

Chandramohan V, Bao X, Yu X, Parker S, McDowall C, Yu YR, Healy P, Desjardins A, Gunn MD, Gromeier M, Nair SK, Pastan IH, Bigner DD.

J Immunother Cancer. 2019 May 29;7(1):142. doi: 10.1186/s40425-019-0614-0.

2.

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.

Yu X, Dobrikov M, Keir ST, Gromeier M, Pastan IH, Reisfeld R, Bigner DD, Chandramohan V.

PLoS One. 2019 Jan 9;14(1):e0210608. doi: 10.1371/journal.pone.0210608. eCollection 2019.

3.

Ribosomal RACK1:Protein Kinase C βII Modulates Intramolecular Interactions between Unstructured Regions of Eukaryotic Initiation Factor 4G (eIF4G) That Control eIF4E and eIF3 Binding.

Dobrikov MI, Dobrikova EY, Gromeier M.

Mol Cell Biol. 2018 Sep 14;38(19). pii: e00306-18. doi: 10.1128/MCB.00306-18. Print 2018 Oct 1.

4.

Ribosomal RACK1:Protein Kinase C βII Phosphorylates Eukaryotic Initiation Factor 4G1 at S1093 To Modulate Cap-Dependent and -Independent Translation Initiation.

Dobrikov MI, Dobrikova EY, Gromeier M.

Mol Cell Biol. 2018 Sep 14;38(19). pii: e00304-18. doi: 10.1128/MCB.00304-18. Print 2018 Oct 1.

5.

Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells.

Walton RW, Brown MC, Sacco MT, Gromeier M.

J Virol. 2018 Sep 12;92(19). pii: e00879-18. doi: 10.1128/JVI.00879-18. Print 2018 Oct 1.

6.

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD.

N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26.

7.

Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma.

Thompson EM, Brown M, Dobrikova E, Ramaswamy V, Taylor MD, McLendon R, Sanks J, Chandramohan V, Bigner D, Gromeier M.

J Neuropathol Exp Neurol. 2018 Aug 1;77(8):696-702. doi: 10.1093/jnen/nly045.

PMID:
29878245
8.

Regulation of Hypoxia-Inducible Factor 1α during Hypoxia by DAP5-Induced Translation of PHD2.

Bryant JD, Brown MC, Dobrikov MI, Dobrikova EY, Gemberling SL, Zhang Q, Gromeier M.

Mol Cell Biol. 2018 May 15;38(11). pii: e00647-17. doi: 10.1128/MCB.00647-17. Print 2018 Jun 1.

9.

Recombinant Poliovirus for Cancer Immunotherapy.

Gromeier M, Nair SK.

Annu Rev Med. 2018 Jan 29;69:289-299. doi: 10.1146/annurev-med-050715-104655.

10.

XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype.

Evans MK, Brown MC, Geradts J, Bao X, Robinson TJ, Jolly MK, Vermeulen PB, Palmer GM, Gromeier M, Levine H, Morse MA, Van Laere SJ, Devi GR.

Cancer Res. 2018 Apr 1;78(7):1726-1738. doi: 10.1158/0008-5472.CAN-17-1667. Epub 2018 Jan 19.

11.

Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.

Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK.

Sci Transl Med. 2017 Sep 20;9(408). pii: eaan4220. doi: 10.1126/scitranslmed.aan4220.

12.

Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.

Chandramohan V, Bryant JD, Piao H, Keir ST, Lipp ES, Lefaivre M, Perkinson K, Bigner DD, Gromeier M, McLendon RE.

Arch Pathol Lab Med. 2017 Dec;141(12):1697-1704. doi: 10.5858/arpa.2016-0580-OA. Epub 2017 Aug 22.

13.

MNK inversely regulates TELO2 vs. DEPTOR to control mTORC1 signaling.

Brown MC, Gromeier M.

Mol Cell Oncol. 2017 Mar 17;4(3):e1306010. doi: 10.1080/23723556.2017.1306010. eCollection 2017.

14.

Gender Differences in Motor Skills of the Overarm Throw.

Gromeier M, Koester D, Schack T.

Front Psychol. 2017 Feb 17;8:212. doi: 10.3389/fpsyg.2017.00212. eCollection 2017.

15.

MNK Controls mTORC1:Substrate Association through Regulation of TELO2 Binding with mTORC1.

Brown MC, Gromeier M.

Cell Rep. 2017 Feb 7;18(6):1444-1457. doi: 10.1016/j.celrep.2017.01.023.

16.

Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.

Holl EK, Brown MC, Boczkowski D, McNamara MA, George DJ, Bigner DD, Gromeier M, Nair SK.

Oncotarget. 2016 Nov 29;7(48):79828-79841. doi: 10.18632/oncotarget.12975.

17.
18.

Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus.

Brown MC, Gromeier M.

Curr Opin Virol. 2015 Aug;13:81-5. doi: 10.1016/j.coviro.2015.05.007. Epub 2015 Jun 12. Review.

19.

Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase.

Brown MC, Bryant JD, Dobrikova EY, Shveygert M, Bradrick SS, Chandramohan V, Bigner DD, Gromeier M.

J Virol. 2014 Nov;88(22):13135-48. doi: 10.1128/JVI.01883-14. Epub 2014 Sep 3.

Supplemental Content

Loading ...
Support Center